Comparing attenuation parameter and liver stiffness measurement using Hepatus and Fibroscan for the evaluation of steatosis and fibrosis in patients with chronic liver disease: A prospective study

Background There are limited studies comparing Hepatus (HP), a novel visual transient elastography device with Fibroscan (FS), one of the most studied and validated non-invasive tests in the field of hepatology. Methodology HP and FS examinations were performed on patients with chronic liver disease by two operators, healthcare providers from different background, twice on each patient, at two different time points, independent of each other. Results The data for 158 patients with 1264 examinations was analysed. There was moderate to strong correlation for attenuation parameter (Spearman’s rho 0.67, p < 0.001) and liver stiffness measurement (LSM) (Spearman’s rho 0.74, p < 0.001) obtained using the two devices. The mean difference (95% limits of agreement) in measurements was 15 (−69–99) dB/m for attenuation parameter and 1.2 (−5.0–7.2) kPa for LSM. There was fair to moderate agreement for diagnosis of steatosis grade >S0, > S1 and >S2 and substantial agreement for diagnosis of unlikely and likely compensated advanced chronic liver disease. The interquartile range (IQR) for attenuation parameter and IQR/median for LSM were lower for HP compared with FS (12 dB/m vs 33 dB/m, p < 0.001, and 13% vs 14%, p < 0.001, respectively). The intra- and inter-observer reliability using both devices were good to excellent with intraclass correlation coefficients of 0.86–0.97. Subgroup analyses demonstrated that agreement between HP and FS was maintained across obese and non-obese patients as well as patients with viral hepatitis and metabolic dysfunction-associated steatotic liver disease. HP had shorter examination time (43 s vs 62 s, p < 0.001) and fewer invalid measurements (0 vs 1, p < 0.001). Conclusion HP demonstrated good comparability and reproducibility with FS for the assessment of hepatic steatosis and fibrosis, with shorter examination time and fewer invalid measurements.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-05
DOI
https://doi.org/10.1371/journal.pone.0359831
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparing attenuation parameter and liver stiffness measurement using Hepatus and Fibroscan for the evaluation of steatosis and fibrosis in patients with chronic liver disease: A prospective study

Anushya Vijayananthan, Wah‐Kheong Chan, Ram Prasad Sinnanaidu, Farahani Khamis et al.
PLoS ONE
Liver Disease Diagnosis and Treatment
article

Comparing attenuation parameter and liver stiffness measurement using Hepatus and Fibroscan for the evaluation of steatosis and fibrosis in patients with chronic liver disease: A prospective study

Anushya Vijayananthan, Wah‐Kheong Chan, Ram Prasad Sinnanaidu, Farahani Khamis, Cain-En Lim, Jin Ying Teh, Xin Tong Ng
article en

Abstract

Background There are limited studies comparing Hepatus (HP), a novel visual transient elastography device with Fibroscan (FS), one of the most studied and validated non-invasive tests in the field of hepatology. Methodology HP and FS examinations were performed on patients with chronic liver disease by two operators, healthcare providers from different background, twice on each patient, at two different time points, independent of each other. Results The data for 158 patients with 1264 examinations was analysed. There was moderate to strong correlation for attenuation parameter (Spearman’s rho 0.67, p < 0.001) and liver stiffness measurement (LSM) (Spearman’s rho 0.74, p < 0.001) obtained using the two devices. The mean difference (95% limits of agreement) in measurements was 15 (−69–99) dB/m for attenuation parameter and 1.2 (−5.0–7.2) kPa for LSM. There was fair to moderate agreement for diagnosis of steatosis grade >S0, > S1 and >S2 and substantial agreement for diagnosis of unlikely and likely compensated advanced chronic liver disease. The interquartile range (IQR) for attenuation parameter and IQR/median for LSM were lower for HP compared with FS (12 dB/m vs 33 dB/m, p < 0.001, and 13% vs 14%, p < 0.001, respectively). The intra- and inter-observer reliability using both devices were good to excellent with intraclass correlation coefficients of 0.86–0.97. Subgroup analyses demonstrated that agreement between HP and FS was maintained across obese and non-obese patients as well as patients with viral hepatitis and metabolic dysfunction-associated steatotic liver disease. HP had shorter examination time (43 s vs 62 s, p < 0.001) and fewer invalid measurements (0 vs 1, p < 0.001). Conclusion HP demonstrated good comparability and reproducibility with FS for the assessment of hepatic steatosis and fibrosis, with shorter examination time and fewer invalid measurements.

PLoS ONEVol. 21(11)
University of Malaya (MY)
Openalex Percentile: Top 17%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon